Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Lemonade Inc (LMND) vs Pfizer Inc (PFE) Price & Performance

Lemonade IncTrade
Pfizer IncTrade

Price performance (Past 24H)

Key statistics

Lemonade Inc vs Pfizer Inc — how do they compare? Lemonade Inc trades at $52.87 (market cap $4.09B), while Pfizer Inc trades at $26.4 (market cap $151.73B). The key difference: Pfizer Inc is far larger — about 37.1× Lemonade Inc's market cap, and Pfizer Inc pays a 6.46% dividend while Lemonade Inc pays none. Which is the better fit depends on your goals.

LMNDPFE
Market Cap
$4.09B$151.73B
Sector
FinancialsHealth
52-Week High
$96.57$28.56
52-Week Low
$47.38$23.60
Enterprise Value
$3.95B$203.22B
Volume
29,869,932
Dividend Yield
6.46%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Lemonade Inc

Lemonade (LMND) trades at $52.68, down 0.49% on the day, with technical indicators showing a bearish bias. The company reported Q2 2026 revenue growth of 79% year-over-year and has beaten EPS estimates for three consecutive quarters, yet remains unprofitable with a net income margin of -22.43% in 2025. Recent news highlights management's presentation at an Oppenheimer conference and ongoing expansion of renters insurance products.

The outlook is mixed; accelerating premium growth and a path to positive adjusted EBITDA by Q4 2026 offer upside potential, but high valuation multiples, persistent losses, and bearish technical signals present significant risks. Analyst consensus is evenly split, reflecting uncertainty around the profitability timeline.

Pfizer Inc

Pfizer (PFE) trades at $27.05, up 1.16% with a bullish technical signal and consistent earnings beats in recent quarters. Revenue remains stable around $62-63 billion, though net income is projected to decline in 2026. The stock shows strong profitability margins and a solid balance sheet, but faces headwinds from patent expirations and competitive pressures.

The outlook is mixed: valuation multiples appear reasonable, and analyst consensus leans hold with a $27.86 target. Key risks include execution on pipeline catalysts and margin compression. Upside depends on successful drug launches and cost management amid a challenging revenue environment.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Lemonade Inc

Lemonade Inc operates in the insurance industry. The company offers digital and artificial intelligence based platform for various insurances and for settling claims and paying premiums. The platform ensures transparency in issuing policies and settling disputes.

Read more on LMND

About Pfizer Inc

Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.

Read more on PFE